Target Name: CCL4
NCBI ID: G6351
Review Report on CCL4 Target / Biomarker Content of Review Report on CCL4 Target / Biomarker
CCL4
Other Name(s): C-C motif chemokine ligand 4 | PAT 744 | C-C motif chemokine 4 | SIS-gamma | ACT-2 | lymphocyte activation gene 1 protein | macrophage inflammatory protein 1-beta | G-26 T-lymphocyte-secreted protein | small inducible cytokine A4 (homologous to mouse Mip-1b) | SCYA2 | Lymphocyte activation gene 1 protein | LAG-1 | CCL4_HUMAN | MIP-1beta | Lymphocyte-activation gene 1 | AT744.1 | MIP1B1 | MIP-1-beta(3-69) | Small-inducible cytokine A4 | MIP-1-beta | Protein H400 | chemokine (C-C motif) ligand 4 | LAG1 | secreted protein G-26 | MIP-1-beta(1-69) | T-cell activation protein 2 | ACT2 | MIP1B | Small inducible cytokine A4 | G-26 | SCYA4 | HC21 | Macrophage inflammatory protein 1-beta

CCL4: A Potential Drug Target and Biomarker for Cancer

CCL4, also known as chemokine ligand 4, is a protein that is expressed in various cell types throughout the body. It is a member of the chemokine family, which are a group of cytokines that play a crucial role in the regulation of cellular behavior. CCL4 is known for its ability to interact with the protein PD-L1, which is a known regulator of immune responses.

The CCL4 protein has been shown to have various functions in the body, including the regulation of inflammation, immune cell proliferation, and cell survival. It has also been shown to play a role in the development and progression of various diseases, including cancer.

One of the most promising aspects of CCL4 is its potential as a drug target. CCL4 has been shown to interact with PD-L1, which makes it a potential target for cancer treatment.PD-L1 is a protein that is expressed in various tissues throughout the body, including immune cells, and has been shown to play a role in the regulation of immune responses. It is a known regulator of T cell responses, and has been shown to promote the development of cancer.

Research has shown that CCL4 can interact with PD-L1 and inhibit its activity. This suggests that CCL4 may be a useful drug target for cancer treatment. Studies have also shown that inhibiting CCL4 activity with small molecules has potential therapeutic benefits.

Another promising aspect of CCL4 is its role as a biomarker. CCL4 has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. It has also been shown to be involved in the development and progression of various diseases, including cancer.

Research has shown that measuring CCL4 levels in cancer cells can be a useful biomarker for the diagnosis and prognosis of cancer. Studies have also shown that levels of CCL4 have been correlated with the severity of cancer, which suggests that it may be a useful biomarker for monitoring the effectiveness of cancer treatments.

In conclusion, CCL4 is a protein that has been shown to play a role in various cellular processes throughout the body. Its potential as a drug target and biomarker makes it an attractive target for further research. Further studies are needed to fully understand the role of CCL4 in the regulation of cellular processes and its potential as a drug and biomarker.

Protein Name: C-C Motif Chemokine Ligand 4

The "CCL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19